Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

Clinical data of the control and CoA cases in our cohort. by Inmaculada Villanueva-Baxarias (21454246)

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

Changes in clinical variables. by Karel Joineau (21799908)

Subjects:

Decreased hypotaurine levels within cells lacking the ADO gene in U251 cells. by Hong Tian (169626)

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

“…Univariate GEE showed that a larger AL elongation in the initial 4 months was significantly associated with AL changes at 6 months (β = 0.354, <i><i>P</i></i> = 0.020, 6 ~ 12 months period from baseline) and 12 months (β = 0.560, <i><i>P</i></i> = 0.045, 6 ~ 18 months period from baseline) after that period in all myopic eyes.…”

Supplementary Material for: Allopurinol Use is Associated With Decreased Incidence of Hepatic Decompensation and Overall Mortality Among Individuals With Cirrhosis: a Propensity-ma... by figshare admin karger (2628495)

“…Conclusion: In a propensity-score matched analysis of a large national database, individuals with cirrhosis and allopurinol use had significantly lower risk of hepatic decompensation and overall mortality. …”

The Vancouver Scar Scale. by Na Wang (193263)

Subjects:

S1 Dataset - by Na Wang (193263)

Subjects:

Numerical Rating Scale (NRS). by Na Wang (193263)

Subjects:

Mammary fistula (n(%)). by Na Wang (193263)

Subjects:

Forest maps affecting lactation outcomes. by Na Wang (193263)

Subjects:

Postoperative drainage(ml) (M(IQR)). by Na Wang (193263)

Subjects:

Introgression decreases allelic shuffling. by Enrique J. Schwarzkopf (6579275)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

Subjects: